| 7.53 0.14 (1.89%) | 11-28 14:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.62 | 1-year : | 12.41 |
| Resists | First : | 9.1 | Second : | 10.62 |
| Pivot price | 6.21 |
|||
| Supports | First : | 6.82 | Second : | 5.42 |
| MAs | MA(5) : | 6.88 |
MA(20) : | 6.24  |
| MA(100) : | 10.22 |
MA(250) : | 12.89 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 76.9 |
D(3) : | 77.7 |
| RSI | RSI(14): 57.9 |
|||
| 52-week | High : | 23.88 | Low : | 5.42 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ANVS ] has closed Bollinger Bands are 12.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.01 - 8.04 | 8.04 - 8.07 |
| Low: | 6.65 - 6.68 | 6.68 - 6.71 |
| Close: | 7.34 - 7.39 | 7.39 - 7.44 |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Mon, 27 Nov 2023
Is it Time to Dump Annovis Bio Inc (ANVS) Stock After it Has Risen 26.85% in a Week? - InvestorsObserver
Mon, 27 Nov 2023
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections - Yahoo Finance
Wed, 08 Nov 2023
Annovis Bio Announces Third Quarter 2023 Financial Results and ... - GlobeNewswire
Mon, 30 Oct 2023
Annovis Bio Announces Launch of Proposed Public Offering - Yahoo Finance
Tue, 24 Oct 2023
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference - Yahoo Finance
Thu, 12 Oct 2023
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 29.5 (%) |
| Held by Institutions | 8.4 (%) |
| Shares Short | 522 (K) |
| Shares Short P.Month | 338 (K) |
| EPS | -4.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.74 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -124.1 % |
| Return on Equity (ttm) | -227.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -1.56 |
| PEG Ratio | 0 |
| Price to Book value | 10.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|